591 



fleet the precise amount of "tar" and nicotine that each individual smoker actually 

 receives. But we do believe that smokers can expect to receive lower amounts of 

 those constituents from lower-rated brands than from higher-rated brands, and that 

 the FTC test method therefore reliably ranks cigarettes in terms of "tar" and nico- 

 tine deliveries. EPA's mileage figures may not reflect the actual experience of indi- 

 vidual drivers, but EPA is correct that a Cadillac delivers fewer miles per gedlon 

 than a Honda. 



Hopefvilly our testimony today will help to clear up some of the misconceptions 

 that currently exist about nicotine in cigarettes. 



On April 5, Dr. Kessler wrote me a letter asking to arrange a meeting between 

 FDA representatives and members of our research, scientific, technical, and produc- 

 tion staffs to review relevant information. I have responded to Dr. Kessler's request 

 and anticipate that such a meeting will take place shortly. 



Mr. Waxman. Next we'll hear from Andrew Tisch, chairman and 

 CEO of Lorillard Tobacco Company. 

 OK. Thank you. 



TESTIMONY OF ANDREW H. TISCH 



Mr, TiSCH. Thank you, Mr. Chairman. At the committee's re- 

 quest, I have submitted for the record at this hearing a written 

 statement in response to each of the questions set forth in your in- 

 vitation letter. In normal circumstances I would be happy to sum- 

 marize that statement orally and then respond to any questions 

 you or the members of the committee might have. 



But these are not normal circumstances, Mr. Chairman, you 

 have made a number of very serious claims and assertions during 

 the press conference that you called yesterday. Claims and asser- 

 tions that question the integrity of our company and of Dr. Alexan- 

 der Spears, who is with me today and testified before this commit- 

 tee on March 25th. 



When a representative of our company called your staff yester- 

 day following a press conference to ask that Dr. Spears be given 

 a separate opportunity to respond to the claims and assertions 

 from your press conference that related to him, we were told that 

 this would not be possible. 



More specifically, we were told that Dr. Spears opportunity to re- 

 spond would be limited to any time that might be left from the 

 time that has been allotted to my testimony or to the question and 

 answer period that is to follow. 



Mr. Chairman, I frankly cannot understand the attitude con- 

 veyed by your staff. Indeed, I am left with no choice but to cede 

 the balance of my time to Dr. Spears to ensure that he will have 

 the adequate opportunity to correct the very serious misstatements 

 and misconceptions that were conveyed in yesterday's press con- 

 ference. 



Mr. Chairman, with your permission, I'd like to ask if Dr. Spears 

 may respond during the rest of my time period? 



Mr. Waxman. Mr. Tisch, we're going to have plenty of oppor- 

 tunity for Dr. Spears to respond. I do have a number of questions 

 to ask of him, he will have his chance. But this is our chance to 

 hear to from you. And we want to hear from you at this point. 



Mr. TiSCH. OK, fine. I must respectfully disagree with that, but 

 you are the boss. 



On behalf of the more than 3,700 employees at Lorillard Tobacco 

 Company, I am pleased to have this opportunity to address you 

 about the issues you identified in your letter to Lorillard of March 



